From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 11 Apr 2020 18:10:39 +0000

To: (b) (6)

Subject: FW: Wpost: Gilead's experimental drug remdesivir shows 'hopeful' signs in

small group of coronavirus patients https://wapo.st/2wzjsy2

Geeez....

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone:
(b) (6)
FAX: (301) 496-4409

E-mail: (b)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Folkers, Greg (NIH/NIAID) [E] (b) (6) >

Sent: Friday, April 10, 2020 5:30 PM

Subject: Wpost: Gilead's experimental drug remdesivir shows 'hopeful' signs in small group of

coronavirus patients https://wapo.st/2wzjsy2

Business

Gilead's experimental drug remdesivir shows 'hopeful' signs in small group of coronavirus patients

Two-thirds of severely ill patients showed improvement in their oxygen therapy level when treated with the antiviral drug